Concussion, Mild Clinical Trial
Official title:
The Effect of Chronic Cannabis Use on Neural Response to Acute Subconcussive Head Impacts
Verified date | February 2023 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this pilot study is to better understand the effects of chronic cannabis (THC) use on the neural responses to subconcussive head impacts, as a form of repetitive soccer headings. The study is designed to identify the physiological changes of cannabis using cohort (THC) and compare it to a nonusing cohort in order to see if the responses to 20 controlled bouts of soccer headings are exacerbated by the chronic cannabis use, diminished to less of a response, or unchanged, through an array of neurologic measures, including cognitive function, ocolar-motor function, autonomic function, and blood biomarkers. The hypothesis is that repetitive subconcussive head impacts will impair cognitive function in worse memory, attention span, and visual and verbal problem solving; this impairment will be greater in the chronic cannabis use groups than non-using group. The blood and salivary biomarkers neurofilament light (NFL) and glial fibrillary acidic protein (GFAP) will be measured in plasma, with the hypothesis that repetitive subconcussive head impacts will significantly increase plasma NFL and GFAP level at 24 hours-post heading and decrease by 72 hours-post heading, while remaining undetectable at 2 hours-post heading; the chronic cannabis use groups will see more severe effects on ocular-motor function than the non-using group. The study aims to determine the differences in acute effects of subconcussive head impacts on eye movement, attention, and language function between chronic cannabis use subjects and non-using subjects by evaluating ocular-motor function with near point of convergence and King-Devick tests. The hypothesis is that repetitive subconcussive head impacts will significantly increase impairments of eye movements, attention, and language function, as well as near point of convergence; the chronic cannabis use groups will see more severe effects on hampered ocular-motor function than the non-using group. Lastly, there is a cold pressor test to assess autonomic nerve function, with the hypothesis that repetitive subconcussive head impacts will decrease autonomic nerve function in chronic cannabis use patients to a greater degree than non-using subjects.
Status | Completed |
Enrollment | 70 |
Est. completion date | December 1, 2021 |
Est. primary completion date | October 1, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 26 Years |
Eligibility | Inclusion Criteria: For Chronic THC User Group 1. being between 18 to 26 years of age 2. self-reported chronic THC use (average use once per week but not dependent)3) at least 3 years of soccer heading experience. For Non-User Cohort 1. being between 18 to 26 years of age 2. self-reported non cannabis use in the past 6 months 3. at least 3 years of soccer heading experience Exclusion Criteria: 1. any head, neck, or face injury in the 1 year prior to the study (e.g., concussion, eye injury); 2. history of vestibular, ocular, or vision dysfunction (e.g., macular degeneration) 3. currently taking any medications affecting balance (e.g., antibiotics) 4. pregnancy 5. HIV 6. any neurological disorders (e.g., seizure disorders, closed head injuries with loss of consciousness greater than 15 minutes, CNS neoplasm, spinal cord injury/surgery, history of stroke) 7. hypertension, cardiac arrhythmia, or pulmonary disease 8. lower extremity injury that would prohibit performing soccer headings 9. metal implants in the head Session-specific exclusion criteria will include: 10. used cannabis within the last 72 hours (verified by saliva cannabis test before intervention) 11. slept less than 4 hours before the 1st and 2nd test day (verified by screening questionnaire) 12. drank any alcoholic drinks or used recreational drugs 72 hours before the 1st test day and during the study period. 13. drank more than 3 cups of coffee before any test sessions 14. glasses are prohibited (contact lenses are okay) for safety purpose for the heading intervention |
Country | Name | City | State |
---|---|---|---|
United States | Indiana University School of Public Health | Bloomington | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acute change in brain-derived blood and saliva biomarkers from pre to 24 hour post-heading | Blood samples will be collected and centrifuged at 1500 x g for ten minutes at 4 degree celsius. Serum and saliva samples will be aliquoted and stored at -80 degree celsius until analysis.
Serum and saliva samples will be assayed for S100B, neurofilament-light (NfL), glial fibrillary acidic protein (GFAP), and tau, and UCH-L1. All expression levels in pg/mL. |
Blood samples will be collected at pre- and 24 hour post-heading | |
Primary | Acute change in brain-derived blood and saliva biomarkers from pre to 2 hour post-heading | Blood samples will be collected and centrifuged at 1500 x g for ten minutes at 4 degree celsius. Serum and saliva samples will be aliquoted and stored at -80 degree celsius until analysis.
Serum and saliva samples will be assayed for S100B, neurofilament-light (NfL), glial fibrillary acidic protein (GFAP), and tau, and UCH-L1. All expression levels in pg/mL. |
Blood and saliva samples will be collected at pre- and 2 hour post-heading | |
Primary | Acute change in neurocognitive function from pre to 2 hour post-heading | Participants will complete a computerized neurocognitive assessment (Immediate Post-Concussion Assessment and Cognitive Testing). | Neurocognitive function will be assessed at pre- and 2 hour post-heading | |
Primary | Acute change in neurocognitive function from pre to 24 hour post-heading | Participants will complete a computerized neurocognitive assessment (Immediate Post-Concussion Assessment and Cognitive Testing). | Neurocognitive function will be assessed at pre- and 24 hour post-heading | |
Primary | Acute change in ocular-motor function from pre to 2 hour post-heading | Participants will undergo 2 ocular-motor assessments: 1) near-point of convergence and 2) King-Devick Test--a brief assessment of saccadic eye movements, attention, and visual and language processing. | Ocular-motor function will be assessed at pre- and 2 hour post-heading | |
Primary | Acute change in ocular-motor function from pre to 24 hour post-heading | Participants will undergo 2 ocular-motor assessments: 1) near-point of convergence and 2) King-Devick Test--a brief assessment of saccadic eye movements, attention, and visual and language processing. | Ocular-motor function will be assessed at pre- and 24 hour post-heading | |
Secondary | Acute change in brain-derived blood and saliva biomarkers from pre to 72 hour post-heading | Blood samples will be collected and centrifuged at 1500 x g for ten minutes at 4 degree celsius. Serum and saliva samples will be aliquoted and stored at -80 degree celsius until analysis.
Serum and saliva samples will be assayed for S100B, neurofilament-light (NfL), glial fibrillary acidic protein (GFAP), and tau, and UCH-L1. All expression levels in pg/mL. |
Blood and saliva samples will be collected at pre- and 72 hour post-heading | |
Secondary | Acute change in neurocognitive function from pre to 72 hour post-heading | Participants will complete a computerized neurocognitive assessment (Immediate Post-Concussion Assessment and Cognitive Testing). | Neurocognitive function will be assessed at pre- and 72 hour post-heading | |
Secondary | Acute change in ocular-motor function from pre to 72 hour post-heading | Participants will undergo 2 ocular-motor assessments: 1) near-point of convergence and 2) King-Devick Test--a brief assessment of saccadic eye movements, attention, and visual and language processing. | Ocular-motor function will be assessed at pre- and 72 hour post-heading | |
Secondary | Acute change in autonomic nerve function from pre to 2 hour post-heading | Participants will undergo cold-pressor testing (CPT). CPT is a general assessment of the ability of the sympathetic nervous system to become activated. This test will be performed by submerging a participant's hand into cold water for 2 minutes while autonomic and hemodynamic variables are recorded. At each data collection, participants will be instrumented for the measurement of heart rate (electrocardiogram) and continuous blood pressure. Participants will rest quietly for ~10mins before the CPT begins. The test takes 2 minutes.
Mean arterial pressure (in mm/Hg) is the outcome measure. |
Autonomic response will be assessed at pre- and 2 hour post-heading | |
Secondary | Acute change in autonomic nerve function from pre to 24 hour post-heading | Participants will undergo cold-pressor testing (CPT). CPT is a general assessment of the ability of the sympathetic nervous system to become activated. This test will be performed by submerging a participant's hand into cold water for 2 minutes while autonomic and hemodynamic variables are recorded. At each data collection, participants will be instrumented for the measurement of heart rate (electrocardiogram) and continuous blood pressure. Participants will rest quietly for ~10mins before the CPT begins. The test takes 2 minutes.
Mean arterial pressure (in mm/Hg) is the outcome measure. |
Autonomic response will be assessed at pre- and 24 hour post-heading | |
Secondary | Acute change in autonomic nerve function from pre to 72 hour post-heading | Participants will undergo cold-pressor testing (CPT). CPT is a general assessment of the ability of the sympathetic nervous system to become activated. This test will be performed by submerging a participant's hand into cold water for 2 minutes while autonomic and hemodynamic variables are recorded. At each data collection, participants will be instrumented for the measurement of heart rate (electrocardiogram) and continuous blood pressure. Participants will rest quietly for ~10mins before the CPT begins. The test takes 2 minutes.
Mean arterial pressure (in mm/Hg) is the outcome measure. |
Autonomic response will be assessed at pre- and 72 hour post-heading |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05849064 -
Concussion Treatment in Older Adults
|
N/A | |
Terminated |
NCT04586179 -
A Comparison Between Cardiovascular Exercise Modes Following Sport Related Concussion
|
N/A | |
Not yet recruiting |
NCT05943561 -
Biomarkers in Concussion
|
||
Completed |
NCT03236389 -
Brain Dynamics in Response to Jugular Vein Compression
|
N/A | |
Completed |
NCT02721537 -
Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes
|
N/A | |
Completed |
NCT01832714 -
Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event
|
||
Completed |
NCT04560400 -
Reverse King-Devick Test and History of Multiple Concussions
|
N/A | |
Completed |
NCT03678077 -
Trends in Cohabitation Status, Academic Achievement and Socio-economic Indicators After Mild Traumatic Brain Injury
|
||
Recruiting |
NCT05262361 -
Persistent Post-Concussion Symptoms With Convergence Insufficiency
|
N/A | |
Recruiting |
NCT05105802 -
Mindfulness-Based Intervention for Mild Traumatic Brain Injury
|
N/A | |
Terminated |
NCT03123822 -
Spectacles Lens in Concussed Kids
|
N/A | |
Completed |
NCT04074486 -
Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC
|
||
Withdrawn |
NCT04578743 -
Exercise as Concussion Therapy Trial- 2
|
Phase 2 | |
Completed |
NCT03170856 -
The Effects of a Sub-maximal Exercise Program on Adolescents Who Sustained a Concussion
|
N/A | |
Completed |
NCT03671083 -
Validation of Brain Function Assessment Algorithm for mTBI/Concussion
|
||
Completed |
NCT05069948 -
Delivery of Digital Cognitive Behavioural Therapy Following Concussion
|
N/A | |
Recruiting |
NCT03889483 -
Neurophysiological Measurements Using the NeuroCatchâ„¢ Platform in Pediatric Concussion
|
N/A | |
Withdrawn |
NCT02959294 -
Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries
|
Early Phase 1 | |
Recruiting |
NCT06093295 -
Non-invasive Brain Stimulation and Injury Risk Biomechanics
|
N/A | |
Completed |
NCT02280304 -
Meditation in Veterans With PTSD and Mild TBI
|
N/A |